Abbott’s Absorb fares well again against Xience in Japanese study

Abbott (NYSE:ABT) today released positive data from a Japanese study of its Absorb fully dissolving heart stent that pitted it against its own Xience permanent drug eluting stent. The results were announced at the European Society of Cardiology’s annual meeting in London. The 400 patient multi-center, randomized Absorb study, published in the European Heart Journal, set out to compare the safety and effectiveness of the 2 stents in patients with coronary artery disease. The study reported a rate of target lesion failure, the primary endpoint of the trial, of 4.2% for the Absorb stent and 3.8% for its Xience stent at 1 year. Target lesion failure includes heart disease-related deaths, heart attacks due to the treated vessel and repeat procedures. Rates of angiographic late lumen loss, the trial’s secondary endpoint, were also similar between the 2 stents, according to the study, varying by 0.02 mm at maximum. Stent thrombosis rates were similar between the cohorts at 1.5%, and the rate of repeat procedures was 2.6% for the Absorb group and 2.3% for the Xience group. “The results of the Absorb Japan study  continue to affirm that Absorb shows strong performance near-term and preserves the vessel for potential future procedures. Fully dissolving heart stents are the next evolution in percutaneous coronary intervention and are designed to leave nothing behind in the body, thus restoring the vessel more naturally over time, which cannot be achieved with a perma...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Drug-Eluting Stents Abbott Source Type: news